Holding(s) in Company

RNS Number : 5539D

Dechra Pharmaceuticals PLC

03 December 2009

 



TR-1:NOTIFICATION OF MAJOR INTEREST IN SHARES
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii				Dechra Pharmaceuticals PLC
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights					X
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: iii		BlackRock, Inc.
4. Full name of shareholder(s)   (if different from 3.):iv
5. Date of the transaction and date on which the threshold is crossed or reached: v		1st December 2009
6. Date on which issuer notified:		3rd December 2009
7. Threshold(s) that is/are crossed or reached: vi, vii		Holding has gone above 5%

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB0009633180

N/A

N/A

N/A

N/A

3,327,206

N/A

5.05%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/  Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

3,327,206

5.05%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
On 1 December 2009, the Barclays Global Investors (BGI) business was acquired by BlackRock, Inc. The combined holdings of BlackRock, Inc. following this acquisition triggered this disclosure requirement. BlackRock Investment Management (UK) Limited - 3,327,206 (5.05%)
Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:	BlackRock Compliance Disclosures Team
14. Contact name:	Stuart Watchorn
15. Contact telephone number:	020 7743 5741; [e-mail]

Note: Annex should only be submitted to the FSA not the issuer
Annex: Notification of major interests in share
A: Identity of the persons or legal entity subject to the notification obligation
Full name  (including legal form of legal entities)	BlackRock Inc
Contact address  (registered office for legal entities)	33 King William Street, London EC4R 9AS
Phone number & email	020 7743 5741; [e-mail]
Other useful information  (at least legal representative for legal persons)	Stuart Watchorn
B: Identity of the notifier, if applicable
Full name
Contact address
Phone number & email
Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation)
C: Additional information
For notes on how to complete form TR-1 please see the FSA website.

 

END

 

 

HOLZGMGZDFKGLZM